Wings Capital Partners

What is Wings Capital Partners?

Wings Capital Partners, known as Fund+, is an open-ended Venture Capital Fund based in Groot Begijnhof 60, Leuven, Belgium, BE-3000. They specialize in long-term equity investments in the Life Sciences sector, with a particular focus on innovative companies located in Belgium.

Their investment strategy is centered around early stage, expansion, later stage, management buyouts/leveraged buyouts (MBO/LBO), and special situations.

By leveraging their expertise in equity, they aim to create sustainable shareholder value, contribute to the development of a leadership position in the Life Sciences sector, and generate a tangible, beneficial societal impact. They proudly foster innovation by investing in transformative companies that drive progress in the aerospace and defense industries as well.

Fund+ actively engages with their portfolio companies and provides support beyond financial resources. Their current and past portfolio showcases investments in promising life sciences ventures that range from therapeutics to medical technology.

They highlight latest advancements of their portfolio companies such as Novadip's interim results with NVDX3 for bone treatment, Confo Therapeutics' Series B Financing, and Tubulis' clinical trial participation for cancer treatment, indicating an active role in shaping the industry's future.

The fund takes pride in its team and board members who collectively drive the firm’s mission forward. They invite innovative projects that align with their investment thesis and offer contact avenues for potential collaboration.